Autologous Dendritic Cells in Combination With Chemotherapy Restore Responsiveness of T Cells in Breast Cancer Patients: A Single-Arm Phase I/II Trial

David A Bernal-Estévez, Mauren A Ortíz Barbosa, Paola Ortíz-Montero, Claudia Cifuentes, Ramiro Sánchez, Carlos A Parra-López

Research output: Contribution to journalArticlepeer-review

17 Scopus citations

Abstract

INTRODUCTION: Animal studies and preclinical studies in cancer patients suggest that the induction of immunogenic cell death (ICD) by neoadjuvant chemotherapy with doxorubicin and cyclophosphamide (NAC-AC) recovers the functional performance of the immune system. This could favor immunotherapy schemes such as the administration of antigen-free autologous dendritic cells (DCs) in combination with NAC-AC to profit as cryptic vaccine immunogenicity of treated tumors.

OBJECTIVE: To explore the safety and immunogenicity of autologous antigen-free DCs administered to breast cancer patients (BCPs) in combination with NAC-AC.

MATERIALS AND METHODS: A phase I/II cohort clinical trial was performed with 20 BCPs treated with NAC-AC [nine who received DCs and 11 who did not (control group)]. The occurrence of adverse effects and the functional performance of lymphocytes from BCPs before and after four cycles of NAC-AC receiving DCs or not were assessed using flow cytometry and compared with that from healthy donors (HDs). Flow cytometry analysis using manual and automated algorithms led us to examine functional performance and frequency of different lymphocyte compartments in response to a stimulus in vitro. This study was registered at clinicaltrials.gov (NCT03450044).

RESULTS: No grade II or higher adverse effects were observed associated with the transfer of DCs to patients during NAC-AC. Interestingly, in response to the in vitro stimulation, deficient phosphorylation of Zap70 and AKT proteins observed before chemotherapy in most patients' CD4 T cells significantly recovered after NAC-AC only in patients who received DCs.

CONCLUSIONS: The transfer of autologous DCs in combination with NAC-AC in BCPs is a safe procedure. That, in BCPs, the administration of DCs in combination with NAC-AC favors the recovery of the functional capacity of T cells suggests that this combination may potentiate the adjuvant effect of ICD induced by NAC-AC on T cells and, hence, potentiate the immunogenicity of tumors as cryptic vaccines.

Original languageEnglish
Pages (from-to)669965
JournalFrontiers in immunology
Volume12
DOIs
StatePublished - 2021

Keywords

  • Antineoplastic Combined Chemotherapy Protocols/adverse effects
  • Breast Neoplasms/immunology
  • Cancer Vaccines/adverse effects
  • Chemotherapy, Adjuvant
  • Colombia
  • Cyclophosphamide/therapeutic use
  • Dendritic Cells/immunology
  • Doxorubicin/therapeutic use
  • Female
  • Humans
  • Immunotherapy, Adoptive/adverse effects
  • Lymphocytes, Tumor-Infiltrating/immunology
  • Middle Aged
  • Neoadjuvant Therapy
  • T-Lymphocytes/immunology
  • Time Factors
  • Treatment Outcome
  • Tumor Microenvironment

Fingerprint

Dive into the research topics of 'Autologous Dendritic Cells in Combination With Chemotherapy Restore Responsiveness of T Cells in Breast Cancer Patients: A Single-Arm Phase I/II Trial'. Together they form a unique fingerprint.

Cite this